Search Results - "Lemonnier, Jerome"

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers by Loi, Sherene, Drubay, Damien, Adams, Sylvia, Pruneri, Giancarlo, Francis, Prudence A, Lacroix-Triki, Magali, Joensuu, Heikki, Dieci, Maria Vittoria, Badve, Sunil, Demaria, Sandra, Gray, Robert, Munzone, Elisabetta, Lemonnier, Jerome, Sotiriou, Christos, Piccart, Martine J, Kellokumpu-Lehtinen, Pirkko-Liisa, Vingiani, Andrea, Gray, Kathryn, Andre, Fabrice, Denkert, Carsten, Salgado, Roberto, Michiels, Stefan

“…The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs)…”
Get full text

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer by Loi, Sherene, Salgado, Roberto, Adams, Sylvia, Pruneri, Giancarlo, Francis, Prudence A., Lacroix-Triki, Magali, Joensuu, Heikki, Dieci, Maria Vittoria, Badve, Sunil, Demaria, Sandra, Gray, Robert, Munzone, Elisabetta, Drubay, Damien, Lemonnier, Jerome, Sotiriou, Christos, Kellokumpu-Lehtinen, Pirkko Liisa, Vingiani, Andrea, Gray, Kathryn, André, Fabrice, Denkert, Carsten, Piccart, Martine, Roblin, Elvire, Michiels, Stefan

“…The importance of integrating biomarkers into the TNM staging has been emphasized in the 8 th Edition of the American Joint Committee on Cancer (AJCC) Staging…”
Get full text

Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials by Rassy, Elie, Filleron, Thomas, Viansone, Alessandro, Lacroix-Triki, Magali, Rivera, Sofia, Desmoulins, Isabelle, Serin, Daniel, Canon, Jean Luc, Campone, Mario, Gonçalves, Anthony, Levy, Christelle, Cottu, Paul, Petit, Thierry, Eymard, Jean-Christophe, Debled, Marc, Bachelot, Thomas, Dalenc, Florence, Roca, Lise, Lemonnier, Jerôme, Delaloge, Suzette, Pistilli, Barbara

“…Purpose We aimed to determine the pattern of isolated local recurrences (ILR) in women with stage II-III hormone receptor-positive and human epidermal growth…”
Get full text

Bias reduction using combined stain normalization and augmentation for AI-based classification of histological images by Franchet, Camille, Schwob, Robin, Bataillon, Guillaume, Syrykh, Charlotte, Péricart, Sarah, Frenois, François-Xavier, Penault-Llorca, Frédérique, Lacroix-Triki, Magali, Arnould, Laurent, Lemonnier, Jérôme, Alliot, Jean-Marc, Filleron, Thomas, Brousset, Pierre

“…Artificial intelligence (AI)-assisted diagnosis is an ongoing revolution in pathology. However, a frequent drawback of AI models is their propension to make…”
Get full text

Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response by Boughdad, Sarah, Champion, Laurence, Becette, Veronique, Cherel, Pascal, Fourme, Emmanuelle, Lemonnier, Jerome, Lerebours, Florence, Alberini, Jean-Louis

“…Neoadjuvant endocrine therapy (NET) has shown efficacy in terms of clinical response and surgical outcome in postmenopausal patients with estrogen…”
Get full text

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial by Bidard, François-Clément, Hardy-Bessard, Anne-Claire, Bachelot, Thomas, Pierga, Jean-Yves, Canon, Jean-Luc, Clatot, Florian, Andre, Fabrice, De La Motte Rouge, Thibault, Pistilli, Barbara, Dalenc, Florence, Dohollou, Nadine, Arsene, Olivier, Petit, Thierry, Riedl, Cécilia, Morvan, François, Marti, Adina, Lachaier, Emma, Achille, Mihaela, Gozy, Michel, Escande, Anne, Mille, Dominique, Trouboul, Fanny, Arnould, Laurent, Bieche, Ivan, Pradines, Anne, Lemonnier, Jerome, Berger, Frederique, Delaloge, Suzette

“…Abstract Background: ESR1 mutations are known drivers of resistance to first line aromatase inhibitors (AI)-based therapy in hormone receptor-positive (HR+)…”
Get full text

Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study by Di Meglio, Antonio, Michiels, Stefan, Jones, Lee W., El-Mouhebb, Mayssam, Ferreira, Arlindo R., Martin, Elise, Matias, Margarida, Lohmann, Ana Elisa, Joly, Florence, Vanlemmens, Laurence, Everhard, Sibille, Martin, Anne-Laure, Lemonnier, Jerome, Arveux, Patrick, Cottu, Paul H., Coutant, Charles, Del Mastro, Lucia, Partridge, Ann H., André, Fabrice, Ligibel, Jennifer A., Vaz-Luis, Ines

“…Evidence on how weight loss correlates to health-related quality-of-life (HRQOL) among obese breast cancer (BC) patients is limited. We aimed to evaluate…”
Get full text

Body weight and return to work among survivors of early-stage breast cancer by Di Meglio, Antonio, Menvielle, Gwenn, Dumas, Agnes, Gbenou, Arnauld, Pinto, Sandrine, Bovagnet, Thomas, Martin, Elise, Ferreira, Arlindo R, Vanlemmens, Laurence, Arsene, Olivier, Ibrahim, Mahmoud, Wassermann, Johanna, Martin, Anne Laure, Lemonnier, Jerome, Del Mastro, Lucia, Jones, Lee W, Partridge, Ann H, Ligibel, Jennifer A, Andre, Fabrice, Michiels, Stefan, Vaz Luis, Ines

“…BackgroundMany breast cancer (BC) survivors are employed at diagnosis and are expected to return to work after treatment. Among them, around 50% are overweight…”
Get full text

Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation by Kaabeche, Karim, Lemonnier, Jérome, Le Mée, Sandrine, Caverzasio, Joseph, Marie, Pierre J

“…Fibroblast growth factors (FGFs) play an important regulatory role in skeletal development and bone formation. However, the FGF signaling mechanisms…”
Get full text

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications by Jézéquel, Pascal, Kerdraon, Olivier, Hondermarck, Hubert, Guérin-Charbonnel, Catherine, Lasla, Hamza, Gouraud, Wilfried, Canon, Jean-Luc, Gombos, Andrea, Dalenc, Florence, Delaloge, Suzette, Lemonnier, Jérôme, Loussouarn, Delphine, Verrièle, Véronique, Campone, Mario

“…Heterogeneity and lack of targeted therapies represent the two main impediments to precision treatment of triple-negative breast cancer (TNBC), and therefore,…”
Get full text

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment by Guillon, Jordan, Petit, Coralie, Moreau, Marie, Toutain, Bertrand, Henry, Cécile, Roché, Henry, Bonichon-Lamichhane, Nathalie, Salmon, Jean Paul, Lemonnier, Jérôme, Campone, Mario, Verrièle, Véronique, Lelièvre, Eric, Guette, Catherine, Coqueret, Olivier

“…Senescence is a tumor-suppressive mechanism induced by telomere shortening, oncogenes, or chemotherapy treatment. Although it is clear that this suppressive…”
Get full text

Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study by Kaboré, Elisé G, Guenancia, Charles, Vaz-Luis, Ines, Di Meglio, Antonio, Pistilli, Barbara, Coutant, Charles, Cottu, Paul, Lesur, Anne, Petit, Thierry, Dalenc, Florence, Rouanet, Philippe, Arnaud, Antoine, Arsene, Olivier, Ibrahim, Mahmoud, Wassermann, Johanna, Boileau-Jolimoy, Geneviève, Martin, Anne-Laure, Lemonnier, Jérôme, André, Fabrice, Arveux, Patrick

“…In patients treated with cardiotoxic chemotherapies, the presence of cardiovascular risk factors and previous cardiac disease have been strongly correlated to…”
Get full text

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer by Bortolini Silveira, Amanda, Bidard, François-Clément, Tanguy, Marie-Laure, Girard, Elodie, Trédan, Olivier, Dubot, Coraline, Jacot, William, Goncalves, Anthony, Debled, Marc, Levy, Christelle, Ferrero, Jean-Marc, Jouannaud, Christelle, Rios, Maria, Mouret-Reynier, Marie-Ange, Dalenc, Florence, Hego, Caroline, Rampanou, Aurore, Albaud, Benoit, Baulande, Sylvain, Berger, Frédérique, Lemonnier, Jérôme, Renault, Shufang, Desmoulins, Isabelle, Proudhon, Charlotte, Pierga, Jean-Yves

“…Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are two cancer-derived blood biomarkers that inform on patient prognosis and treatment…”
Get full text

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials by Lerebours, Florence, Pulido, Marina, Fourme, Emmanuelle, Debled, Marc, Becette, Véronique, Bonnefoi, Hervé, Rivera, Sofia, MacGrogan, Gaetan, Mouret-Reynier, Marie-Ange, de Lara, Christine Tunon, Pierga, Jean-Yves, Breton-Callu, Christel, Venat-Bouvet, Laurence, Mathoulin-Pélissier, Simone, de la Motte rouge, Thibault, Dalenc, Florence, Sigal, Brigitte, Bachelot, Thomas, Lemonnier, Jérôme, Quenel-Tueux, Nathalie

“…Background Few data are available on survival and predictive factors in early breast cancer (BC) patients treated with neoadjuvant endocrine therapy (NET)…”
Get full text

Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies by Carene, Dimitri, Tran-Dien, Alicia, Lemonnier, Jérôme, Dalenc, Florence, Levy, Christelle, Pierga, Jean-Yves, Jacot, William, Canon, Jean-Luc, Richon, Catherine, Lacroix, Ludovic, Caux, Christophe, André, Fabrice, Michiels, Stefan

“…Purpose Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 negative (HER2−) early breast cancer (BC) is the most prevalent BC subtype…”
Get full text

Increased Osteoblast Apoptosis in Apert Craniosynostosis : Role of Protein Kinase C and Interleukin-1 by Lemonnier, Jerome, Hay, Eric, Delannoy, Philippe, Fromigue, Olivia, Lomri, Abderrahim, Modrowski, Dominique, Marie, Pierre J

“…Apert syndrome is an autosomal dominant disorder characterized by premature cranial ossification resulting from fibroblast growth factor receptor-2…”
Get full text

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study by Bertucci, François, Prof, Fekih, Mahmoud, MD, Autret, Aurélie, MSc, Petit, Thierry, Prof, Dalenc, Florence, MD, Levy, Christelle, MD, Romieu, Gilles, MD, Bonneterre, Jacques, Prof, Ferrero, Jean-Marc, Prof, Kerbrat, Pierre, Prof, Soulie, Patrick, MD, Mouret-Reynier, Marie-Ange, MD, Bachelot, Thomas, MD, Lerebours, Florence, MD, Eymard, Jean-Christophe, MD, Deblock, Mathilde, MD, Lortholary, Alain, MD, Hardy-Bessard, Anne-Claire, MD, Barthelemy, Philippe, MD, Bonnefoi, Hervé, Prof, Charafe-Jauffret, Emmanuelle, Prof, Bidard, François-Clément, MD, Viens, Patrice, Prof, Lemonnier, Jérôme, PhD, Pierga, Jean-Yves, Prof

“…Summary Background Addition of bevacizumab to standard chemotherapy in the neoadjuvant setting in patients with HER2-negative metastatic breast cancer improves…”
Get full text

Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer by Delaloge, Suzette, Dureau, Sylvain, D'Hondt, Véronique, Desmoulins, Isabelle, Heudel, Pierre-Etienne, Duhoux, Francois P., Levy, Christelle, Lerebours, Florence, Mouret-Reynier, Marie A., Dalenc, Florence, Frenel, Jean-Sébastien, Jouannaud, Christelle, Venat-Bouvet, Laurence, Nguyen, Suzanne, Callens, Cécile, Gentien, David, Rapinat, Audrey, Manduzio, Helene, Vincent-Salomon, Anne, Lemonnier, Jérôme, Cottu, Paul

“…Besides their development as additional adjuvant treatments, CDK4/6 inhibitors combined with endocrine therapy could represent less toxic alternatives to…”
Get full text

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14) by Penault-Llorca, Frédérique, Kwiatkowski, Fabrice, Arnaud, Antoine, Levy, Christelle, Leheurteur, Marianne, Uwer, Lionel, Derbel, Olfa, Le Rol, Annick, Jacquin, Jean-Philippe, Jouannaud, Christelle, Quenel-Tueux, Nathalie, Girre, Véronique, Foa, Cyril, Guardiola, Emmanuel, Lortholary, Alain, Catala, Stéphanie, Guiu, Séverine, Valent, Alexander, Boinon, Diane, Lemonnier, Jérome, Delaloge, Suzette

“…Genomic tests can identify ER-positive HER2-negative localized breast cancer patients who may not benefit from adjuvant chemotherapy. Such tests seem…”
Get full text

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial) by Penault-Llorca, Frédérique, Filleron, Thomas, Asselain, Bernard, Baehner, Frederick L, Fumoleau, Pierre, Lacroix-Triki, Magali, Anderson, Joseph M, Yoshizawa, Carl, Cherbavaz, Diana B, Shak, Steven, Roca, Lise, Sagan, Christine, Lemonnier, Jérôme, Martin, Anne-Laure, Roché, Henri

“…The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+)…”
Get full text